Requiring FDA Guidances Does Not Always Advance The Science, Gene Therapy Director Says

OTAT Director Wilson Bryan says important cell and gene therapy guidances came from clear community needs, not user fee program requirements.

Cell therapy
The FDA's infusion of user fee capital for cell and gene therapy work likely will take years to create an impact. • Source: Shutterstock

A guidance mandate in the new US Food and Drug Administration user fee program may feel like a win, but it will only help industry if the agency is ready to opine on the subject, a senior official said.

The FDA must write several new guidances, including some related to cell and gene therapies, as part of the prescription...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By 

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By 

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By 

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By 

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By 

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By 

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.